US-based Cook Medical has introduced its Zilver PTX drug-eluting stent in Canada for the treatment of peripheral arterial disease (PAD) in the superficial femoral artery (SFA).
The launch of the product was performed at the Canadian Interventional Radiology Association (CIRA) meeting in Montreal, Canada.
Cook Medical Peripheral Intervention clinical division vice-president Mark Breedlove said launching Zilver PTX in Canada brings the benefits of drug-eluting stents to Canadian PAD patients.
“We’re very pleased to be the company that introduces this technology in Canada,” Breedlove said.
The device is a self-expanding metal stent coated with the drug paclitaxel, which is absorbed by the surrounding tissues to prevent the growth of scar tissue that can reclog the artery.
Zilver PTX is indicated for use in treating new or recurring lesions as long as 140mm per leg.
In Canada, the company will sell Zilver PTX in 40mm, 60mm, 80mm and 100mm in lengths and in 6mm and 7mm diameters.
The four-year data from the international Zilver PTX randomised trial shows that 75% of patients treated with Zilver PTX maintained blood flow in the SFA at four years compared with 57.9% patency for patients who received a bare-metal Zilver stent.
The initial launch of Zilver PTX took place in 2009 and the device has since been used to treat more than 25,000 PAD patients.
Currently, the device is available in more than 50 countries across Europe, the Middle East, North and South America, and the Asia-Pacific region.